The Competition Commission of South Africa, is investigating the price of US pharmaceutical manufacturer Gilead Science’s coronavirus treatment remdesivir and prices charged by generic firms to which it granted manufacturing license after a complaint by activists and researchers.
Commission spokesperson Makunga Siyabulela said on Monday, August 31, that the organization received a request from non-profit organisation the Health Justice Initiative (HJI) and Wits research unit Ezintsha to examine the price of remdesivir. “It is … currently under investigation and remedies are likely to be behavioural and/or an administrative penalty, if there is a finding of a contravention,” he said.
Featured News
Japan’s Nippon Steel Eyes Year-End Close on $15B US Steel Deal Amid Political Uncertainty
Nov 7, 2024 by
CPI
Canada Orders Dissolution of TikTok’s Business Amid National Security Concerns
Nov 7, 2024 by
CPI
India Raids Amazon, Flipkart Seller Offices in Foreign Investment Probe
Nov 7, 2024 by
CPI
Canada’s Competition Bureau Seeks Public Feedback on Updated Merger Guidelines
Nov 7, 2024 by
CPI
FTC Adopts Stricter Reporting Rules for Mergers, Delays Expected in 2025
Nov 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI